Navigation Links
Scripps Florida scientist awarded $2.3 million to study dengue fever and related viruses
Date:3/27/2014

JUPITER, FL March 27, 2014 The outbreak of dengue fever that infected some 20 people in Florida's Martin County late last year unnerved many who feared the tropical disease had once again established a foothold in Florida. The last outbreaks occurred in 2009 and 2010 in Key Westbefore that, the disease hadn't struck Florida in more than 70 years.

Now, scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded $2.3 million to study a category of viruses that cause dengue fever, West Nile, yellow fever and other diseases spread by mosquitoes and ticks. These diseases can result in flulike symptoms, extreme pain (dengue has been called "bone-break fever") and, in some cases, encephalitis.

This family of viruses, called "flavivirus," affect some 2.5 billion people worldwide and cause hundreds of thousands of deaths each year. There are no antiviral treatments and a just handful of vaccines that provide protection against only a few of these diseases.

The principal investigator for the new five-year study is TSRI Associate Professor Hyeryun Choe, who will lead the effort to understand the virus's mode of infection and how new therapies might interrupt it.

"Flavivirus uses a very clever method of infection," Choe said. "It's like using a side door to enter a house when the front door is locked."

The viruses take advantage of the process that normally occurs during programmed cell death. During programmed cell death ("apoptosis"), a lipid usually found on the inner side of the cell membranes, specifically phosphatidylserine (PS), shifts to the surface, making itself readily available to any passing cellular stranger. This is where the trouble begins.

When cells are dying from a flavivirus infection, their freshly exposed PS is grabbed by the exiting virus, and phagocytescells that devour invading pathogens and dead and dying cellsengulf the virus as if it were a dying cell. Once engulfed by the phagocyte, the virus quickly turns the cell's own biology on its head, forcing it to produce copies of the virus.

While some viruses (influenza A for example) do not use PS in their life cycle, the flavivirus exploits this opportunity to the hilt. Infection of cells by dengue or West Nile viruses is markedly enhanced when phagocytes express receptors that recognize and bind PS.

It appears, however, that flaviviruses use only a subset of these receptors. The high selectivity, and the potency with which some of these receptors promote flavivirus infection, suggest only a small number of receptors might be effectively targeted to treat these diseases.

"We want to understand which PS receptors contribute the most to flavivirus infections and how we might block them," Choe said. "Our studies are designed to offer insights useful in the development of new therapies."


'/>"/>
Contact: Mika Ono
mikaono@scripps.edu
858-784-2052
Scripps Research Institute
Source:Eurekalert

Related medicine news :

1. Scripps researchers recommend mobile compression device to prevent DVT after joint surgery
2. Scripps Florida scientists find regulator of amyloid plaque buildup in Alzheimers disease
3. Scripps Health Launches Pilot Study of Wireless Vital Signs Device
4. OKeeffe Foundation donates $250,000 to fund Scripps Florida neuroscience training program
5. Scripps Research study underlines potential of new technology to diagnose disease
6. Stemedica and Scripps to Jointly Investigate Therapeutic Effect of Ischemia Tolerant Mesenchymal Stem Cells (itMSC) and Stem Cell Factors in Lung Injury and Sepsis
7. Scripps Florida scientists create new approach to destroy disease-associated RNAs in cells
8. Scripps Florida scientists develop new compound that reverses fatty liver disease
9. Scripps Florida scientist awarded $2.5 million to study inner workings of memory formation
10. Scripps Florida scientists uncover a novel cooperative effort to stop cancer spread
11. Scripps Research Institute study points to potential new therapies for cancer and other diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... ... Emergency rooms provide emergency care to stabilize critical health issues, but emergency ... emergencies at risk of losing a tooth or their smiles. Dr. Marine Martirosyan, ... emergencies include:, , Avulsed or knocked-out teeth , ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... bring together more than 200 of the country’s top healthcare executives to share ... “The true benefit of the Forum is the provider-centric perspective, experience, expertise and ...
(Date:2/10/2016)... ... February 10, 2016 , ... AHRA: The ... and inspirational speaker Jan Fox will serve as keynote speaker at the organization’s ... participants with tools to more effectively communicate with their own organizational staff and ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... digital self-scheduling readily available to physicians. The integration will enable Allscripts users ... select appointments via Everseat’s free mobile app. , The partnership gives Everseat substantial ...
(Date:2/10/2016)... , ... February 10, 2016 , ... The recreational use ... enthusiasts in the state still face a lot of restrictions as to where they ... intended for private, personal use” and that cannabis “may not be consumed openly or ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... 2016 CSI Specialty Group (CSI) expanded its ... the Specialty Pharmacy Podcast. A free, weekly show, the ... real-world education, discussion and context amongst specialty pharmacy peers ... --> The Specialty Pharmacy Podcast, hosted by ... Group Suzette DiMascio, CHE, CMCE, CPC, is available for ...
(Date:2/10/2016)... Switzerland and SAN DIEGO ... , Inc., a global leader in viral gene therapy ... therapy treatments for congestive heart failure and other chronic ... develop a scalable manufacturing process and produce cGMP-grade RT-100 ... trials. --> --> ...
(Date:2/10/2016)... Feb. 10, 2016 Urologix, the market leader ... of Benign Prostatic Hyperplasia (BPH), announces new private ownership ... , a medical device industry veteran of more than ... Liability Company.  Plymouth, Minn. ... Cooled ThermoTherapy™ and Prostiva® RF Therapy, will continue to ...
Breaking Medicine Technology: